Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

1． Novartis AG （NVS）J.P． Morgan 43rd Annual Healthcare Conference （Transcript）：公司在过去十年中成功转型为专注于创新药物的公司，剥离了消费者健康、医疗器械（Alcon）和仿制药（Sandoz）业务。转型期间，公司创新药物业务表现强劲，销售额增长7%，合作运营收入增长14%，利润率提升990个基点。2023年，诺华实现自由 ...

Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...